首页 | 本学科首页   官方微博 | 高级检索  
   检索      


Structure based design of 4-(3-aminomethylphenyl)piperidinyl-1-amides: novel, potent, selective, and orally bioavailable inhibitors of betaII tryptase
Authors:Levell Julian  Astles Peter  Eastwood Paul  Cairns Jennifer  Houille Olivier  Aldous Suzanne  Merriman Gregory  Whiteley Brian  Pribish James  Czekaj Mark  Liang Guyan  Maignan Sebastien  Guilloteau Jean-Pierre  Dupuy Alain  Davidson Jane  Harrison Trevor  Morley Andrew  Watson Simon  Fenton Garry  McCarthy Clive  Romano Joseph  Mathew Rose  Engers Darren  Gardyan Michael  Sides Keith  Kwong Jennifer  Tsay Joseph  Rebello Sam  Shen Liduo  Wang Jie  Luo Yongyi  Giardino Odessa  Lim Heng-Keang  Smith Keith  Pauls Henry
Institution:Drug Innovation and Approval, Aventis Pharmaceuticals, 1041 Route 202-206, Mail Stop N-103A, Bridgewater, NJ 08807-6800, USA. julian.levell@aventis.com
Abstract:Tryptase is a serine protease found almost exclusively in mast cells. It has trypsin-like specificity, favoring cleavage of substrates with an arginine (or lysine) at the P1 position, and has optimal catalytic activity at neutral pH. Current evidence suggests tryptase beta is the most important form released during mast cell activation in allergic diseases. It is shown to have numerous pro-inflammatory cellular activities in vitro, and in animal models tryptase provokes broncho-constriction and induces a cellular inflammatory infiltrate characteristic of human asthma. Screening of in-house inhibitors of factor Xa (a closely related serine protease) identified beta-amidoester benzamidines as potent inhibitors of recombinant human betaII tryptase. X-ray structure driven template modification and exchange of the benzamidine to optimize potency and pharmacokinetic properties gave selective, potent and orally bioavailable 4-(3-aminomethyl phenyl)piperidinyl-1-amides.
Keywords:
本文献已被 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号